Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01913457 · ClinicalTrials.gov registry record

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients

A clinical trial, sponsored by Echosense.

Terminated
Registry status
230
Enrollment target

NCT01913457 is a clinical trial that was terminated before completion, run by Echosense. The registered enrollment target is 230 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01913457 was terminated before completion, sponsored by Echosense.

TERMINATED
Registry status
230 participants
Enrollment target

Study Summary

Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD, EchoSense Ltd., Haifa, Israel). These lung Doppler signals (LDS) are in full synchrony with the cardiac cycle and can be obtained from the lungs, including areas remote from the heart and main pulmonary vessels. The LDS waves typically have peak velocities of up to 30 cm/s and are of relatively high power, making it possible to detect them despite the aforementioned attenuation by the air in the lungs. The LDS are thought to represent the radial wall movement of small pulmonary blood vessels, caused by pressure pulse waves of cardiac origin which propagate throughout the lung vasculature. The LDS may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio-vascular system in general. Pulmonary arterial hypertension (PAH) is a condition characterized by reshaping of the small pulmonary arteries with increase in pulmonary vascular resistance, leading gradually to right-sided cardiac failure. A trans-thoracic echocardiograph (TTE) is a test classically undertaken in order to screen for pulmonary hypertension. However, the systolic pulmonary artery pressure (SPAP) values thereby obtained are often imprecise and depend upon the expertise of the individual carrying out the test. Therefore, the pulmonary arterial pressure and cardiac output values have to be ascertained with a right-sided cardiac catheterization, which is considered the gold-standard, but is invasive. In a pilot study of adult PAH patients (unpublished), lung Doppler signals have been shown to have the potential to diagnose pulmonary hypertension in two different ways: First, by measuring the degree of attenuation of the LDS during acute pressure rise in the chest cavity (i.e. during Valsalva

Interventions

  • RADIATION Ultrasound Doppler

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2013-07
Est. Completion 2021-07-01

Sponsor

Echosense

6 total trials

What the Registry Record Tells You About NCT01913457

The ClinicalTrials.gov registry entry for NCT01913457 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Echosense, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ultrasound Doppler is the first listed.

NCT01913457 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01913457 about?

NCT01913457 is a clinical study titled "Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients". Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD, EchoSense Ltd., Haifa, Israel). These lung Doppler signals (LDS) are i...

What is the current status of trial NCT01913457?

This trial is currently terminated. The enrollment target is 230 participants. The study started on 2013-07. Estimated completion is 2021-07-01.

What interventions are being tested in trial NCT01913457?

The interventions under investigation include: Ultrasound Doppler (RADIATION).

Who is sponsoring clinical trial NCT01913457?

This trial is sponsored by Echosense, which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.